Details of the Drug Reposition

General Information of This Drug (ID: DMTIQF3)

• Drug Name: Treprostinil (DMTIQF3)
• Synonyms: Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Pulmonary hypertension	DIS1RSP5	BB01	Approved	[1]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Peripheral vascular disease	DISXSU1Y	BD4Z	Investigative	[1]

References

• [1] Treprostinil FDA Label